Literature DB >> 19615887

Causes of postoperative mortality after surgery for ovarian cancer.

C G Gerestein1, R A M Damhuis, M de Vries, A Reedijk, C W Burger, G S Kooi.   

Abstract

Residual disease after cytoreductive surgery is an important prognostic factor in patients with advanced stage epithelial ovarian cancer (EOC). Aggressive surgical procedures necessary to achieve maximal cytoreduction are inevitably associated with postoperative morbidity and mortality. To determine causes of postoperative mortality (POM) after surgery for EOC all postoperative deaths in the southwestern part of the Netherlands over a 17-year period were identified and analysed by reviewing medical notes. Between 1989 and 2005, 2434 patients underwent cytoreductive surgery for EOC. Sixty-seven patients (3.1%) died within 30 days after surgery. Postoperative mortality increased with age from 1.5% (26/1765) for the age group 20-69 to 6.6% (32/486) for the age group 70-79 and 9.8% (18/183) for patients aged 80 years or older. Pulmonary failure (18%) and surgical site infection (15%) were the most common causes of death. Only a quarter of deaths resulted from surgical site complications. Our results suggest that causes of postoperative mortality after surgery for EOC are very heterogeneous. Given the impact of general complications, progress in preoperative risk assessment, preoperative preparation and postoperative care seem essential to reduce the occurrence of fatal complications.

Entities:  

Mesh:

Year:  2009        PMID: 19615887     DOI: 10.1016/j.ejca.2009.06.004

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

1.  S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Authors:  U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

2.  Factors predicting postoperative morbidity after cytoreductive surgery for ovarian cancer: a systematic review and meta-analysis.

Authors:  Malika Kengsakul; Gatske M Nieuwenhuyzen-de Boer; Suwasin Udomkarnjananun; Stephen J Kerr; Christa D Niehot; Heleen J van Beekhuizen
Journal:  J Gynecol Oncol       Date:  2022-06-07       Impact factor: 4.756

Review 3.  Considerations in the surgical management of ovarian cancer in the elderly.

Authors:  Carrie Langstraat; William A Cliby
Journal:  Curr Treat Options Oncol       Date:  2013-03

4.  Age is associated with prognosis in serous ovarian carcinoma.

Authors:  Fei Deng; Xia Xu; Mengmeng Lv; Binhui Ren; Yan Wang; Wenwen Guo; Jifeng Feng; Xiaoxiang Chen
Journal:  J Ovarian Res       Date:  2017-06-12       Impact factor: 4.234

5.  Prediction of Postoperative Mortality in Patients with Organ Failure After Gastric Cancer Surgery.

Authors:  Ji-Ho Park; Hyuk-Joon Lee; Seung-Young Oh; Shin-Hoo Park; Felix Berlth; Young-Gil Son; Tae Han Kim; Yeon-Ju Huh; Jun-Young Yang; Kyung-Goo Lee; Yun-Suhk Suh; Seong-Ho Kong; Han-Kwang Yang
Journal:  World J Surg       Date:  2020-05       Impact factor: 3.352

6.  Factors associated with surgical morbidity of primary debulking in epithelial ovarian cancer.

Authors:  Emre Günakan; Yusuf Aytaç Tohma; Mehmet Tunç; Hüseyin Akıllı; Hanifi Şahin; Ali Ayhan
Journal:  Obstet Gynecol Sci       Date:  2019-12-31

7.  Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting.

Authors:  Michalis Liontos; Alkistis Papatheodoridi; Angeliki Andrikopoulou; Nikolaos Thomakos; Dimitrios Haidopoulos; Alexandros Rodolakis; Flora Zagouri; Aristotelis Bamias; Meletios-Athanasios Dimopoulos
Journal:  Curr Oncol       Date:  2021-03-07       Impact factor: 3.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.